Fungal pathogens and COVID-19.

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Mycology

Background:

• The COVID-19 pandemic has been associated with a significant increase in secondary fungal infections among severe cases.
• Factors such as immunosuppression, immunomodulatory therapies, and invasive procedures contribute to heightened susceptibility in COVID-19 patients.
• These fungal infections exacerbate patient outcomes, leading to prolonged hospitalization and increased mortality.

Purpose of the Study:

• To review the epidemiology and clinical impact of secondary fungal infections in COVID-19 patients.
• To highlight common fungal pathogens and their global distribution in this patient population.
• To discuss the challenges in diagnosis and treatment of these infections.

Main Methods:

• Literature review of studies reporting fungal infections in COVID-19 patients.
• Analysis of reported fungal species, prevalence, and geographical distribution.
• Examination of diagnostic hurdles and therapeutic limitations.

Main Results:

• Aspergillosis, invasive candidiasis, and mucormycosis are the most frequently reported fungal infections.
• A global increase in candidiasis and aspergillosis was noted, with mucormycosis outbreaks primarily in India.
• These infections significantly impact patient morbidity and mortality.

Conclusions:

• Secondary fungal infections pose a substantial threat to COVID-19 patients, particularly those in intensive care.
• Diagnostic difficulties and limited treatment options contribute to poor management and higher mortality rates.
• Further research and improved clinical strategies are needed to address this growing public health concern.